Nir Barzilai, MD is a renowned aging researcher and professor of medicine and genetics at the Albert Einstein College of Medicine, where he directs the Institute for Aging Research. Dr. Barzilai is known for his groundbreaking studies on centenarians and the genetic factors that contribute to exceptional longevity. His research focuses on discovering mechanisms behind healthy aging, particularly through his "Targeting Aging with Metformin" (TAME) clinical trial, which investigates the potential of metformin in extending healthspan by delaying age-related diseases. Dr. Barzilai’s approach to longevity is rooted in understanding genetic resilience factors and their application to the general population.
The main goal of Dr. Barzilai's protocol is to delay the onset of age-related diseases, thus extending the period of life spent in good health, also known as healthspan. This protocol is suitable for those seeking to improve their quality of life as they age, particularly older adults and individuals with a genetic predisposition to age-related diseases. Expected benefits include enhanced physical function, reduced risk of metabolic diseases, and improved resilience against aging-associated illnesses.
Dr. Barzilai’s protocol is founded on the following principles:
Dr. Barzilai advocates for a Mediterranean-style diet, high in vegetables, fruits, whole grains, healthy fats (like olive oil), and moderate fish and poultry. This diet is associated with improved metabolic health and longevity. Key recommendations include:
Key supplements that Dr. Barzilai endorses include:
These supplements should be taken according to individual health needs and ideally under medical supervision, particularly metformin, which has specific dosage requirements and potential interactions.
Dr. Barzilai recommends moderate, regular physical activity, particularly:
Dr. Barzilai maintains a routine that includes regular physical exercise and adherence to a Mediterranean diet. While he personally highlights the importance of maintaining metabolic health, he does not specify a rigid daily regimen but emphasizes the consistency of moderate, healthy habits.
To maintain cognitive health, Dr. Barzilai advocates for lifelong learning, social engagement, and stress management. Social interactions and mentally stimulating activities, such as reading or problem-solving, are encouraged to support neuroplasticity and cognitive function.
Dr. Barzilai’s protocol is grounded in extensive research, including studies on centenarians that highlight the role of specific genetic factors in longevity. His TAME trial on metformin has shown promising results in preclinical and observational studies, suggesting it may delay the onset of age-related diseases. Additionally, his research on the Mediterranean diet is well-supported by large cohort studies linking it with lower risks of cardiovascular and metabolic diseases.
Potential risks include gastrointestinal side effects associated with metformin and the need for medical supervision due to potential interactions with other medications. Overuse of certain supplements, such as omega-3 fatty acids, may cause bleeding issues in high doses.
This protocol is especially beneficial for older adults with risk factors for metabolic and cardiovascular diseases. Individuals with a family history of longevity may also find this protocol valuable. Cases within Dr. Barzilai’s research include centenarians with genetic resilience to aging, indicating that genetic screening may further personalize protocol recommendations for others.
x.com/NirBarzilaiMD
us.macmillan.com/books/9781250230867/agelater
Longevity, aging research, healthspan, centenarian genetics, metformin, Mediterranean diet, metabolic health, cardiovascular prevention, personalized longevity, aging delay.